EP3883587A1 - Dietary supplement used to reduce the release of inflammatory agents and related use - Google Patents

Dietary supplement used to reduce the release of inflammatory agents and related use

Info

Publication number
EP3883587A1
EP3883587A1 EP19835836.8A EP19835836A EP3883587A1 EP 3883587 A1 EP3883587 A1 EP 3883587A1 EP 19835836 A EP19835836 A EP 19835836A EP 3883587 A1 EP3883587 A1 EP 3883587A1
Authority
EP
European Patent Office
Prior art keywords
titrated
boswellia
dietary supplement
cells
ananas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19835836.8A
Other languages
German (de)
French (fr)
Inventor
Massimo Defilippi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAYOLY ITALIA S.P.A.
Original Assignee
Biohealth Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohealth Italia Srl filed Critical Biohealth Italia Srl
Publication of EP3883587A1 publication Critical patent/EP3883587A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)

Definitions

  • the present invention refers to a dietary supplement designed to drastically reduce the inflammatory effects in people affected by leukemia with infections from Gram-negative bacteria.
  • monocytes and macrophages synthetize and release in their environment a variety of cytokines and other proteins which perform a central role in the development of acute and chronic inflammations.
  • THP-1 is a human monocyte leukemic cell line; it is known from scientific literature that these cells are capable of producing pro- inflammatory cytokines (THE- 1 , THE-6 and TNF) and chemokines (THE-8 and MCP-1) in reply to a stimulation by
  • LPS Lipo-polysaccharides
  • LPS is a polysaccharide deemed as the main component of the external membrane of Gram-negative bacteria. Recent studies have clarified how LPS is recognized by monocytes and macrophages of the innate immune system; in particular, human monocytes are extremely sensitive to LPS and their response is translated into the expression and the release of many inflammatory cytokines.
  • WO-A1-2010/037213 disclose the various components which make the dietary supplement of the present invention; none of them, however, can be used individually to reduce a release of inflammatory cytokines in patients in whose organism there are leukemic cells of a TPH-1 type.
  • the main object of the present invention is reducing, till almost cancelling, the release of inflammatory cytokines, in patients in whose organism there are leukemic cells of the TPH-1 type, said release being a consequence of the response of said TPH-1 cells to a stimulation with
  • LPS Lipo-polysaccharides
  • Johnst titrated in essential fatty acids , preferably Omega 3 and Omega 6;
  • Ananas (Ananas comosus (L. MERR, stipites) dry extract titrated in bromeline;
  • Boswellia Boswellia sacra Flueck . (syn.
  • Boswellia carteri Birdw . rubber resin
  • fluid extract titrated 4% in acetyl - 11-keto-beta- boswellic acid (AKBA) ;
  • Myrrh (Commiphora myrra, oil-rubber resin) fluid extract , titrated 4% in furan-dienes .
  • said dietary supplement comprises the above four active ingredients, with the following relative concentrations :
  • Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline: 16%;
  • Boswellia Boswellia sacra Flueck . (syn. (Boswellia carteri Birdw. ) , rubber resin) fluid extract , titrated 4% in acetyl -11-keto-beta- boswellic acid (AKBA) : 30%;
  • Figure 1 shows the release of inflammatory cytokines TNF-a, due to the stimulation with LPS, of THP-1 cells as such and pre-treated with a formulation according to the invention
  • Figure 2 shows a Table with a formulation according to the invention subjected to experimentations ;
  • Figure 3 shows a Table with the results of experimentations performed on the formulation of
  • the invention therefore deals with a dietary supplement, to be used to reduce the release of inflammatory cytokines in patients in whose organism there are leukemic cells of the TPH-1 type, such release being a consequence of the response of said TPH-1 cells to a stimulation with Lipo-polysaccharides (LPS) ;
  • the dietary supplement of the invention comprises the following active ingredients :
  • Johnst titrated in essential fatty acids, preferably Omega 3 and Omega 6;
  • Ananas Ananas comosus (L. MERR, stipites) dry extract titrated in bromeline;
  • Boswellia Boswellia sacra Flueck. (syn.
  • Boswellia carter! Birdw . rubber resin) fluid extract , titrated 4% in acetyl-ll-keto-beta- boswellic acid (AKBA) ;
  • Myrrh (Commiphora myrra, oil -rubber resin) fluid extract, titrated 4% in furan-dienes.
  • the dietary supplement of the invention comprises the four above active ingredients, with the following relative concentratios :
  • Buglossoides arvensis seed oil (L. , I.M. Johnst) titrated in essential fatty acids, preferably Omega 3 and Omega 6: 14%;
  • Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline: 16%;
  • Boswellia (Boswellia sacra Flueck. (syn. (Boswellia carter! Birdw. ) , rubber resin) fluid extract , titrated 4% in acetyl- 11-keto-beta- boswellic acid (AKBA) : 30%;
  • extra-virgin olive oil (Olea europaea L., fructus) ;
  • titanium dioxide ,- oleic acid
  • the above described supplement can be packaged in capsules and have the following global composition:
  • Buglossoides arvensis seed oil (L., I.M. Johnst) titrated in essential fatty acids, preferably Omega 3 and Omega 6: 9.764%;
  • Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline: 11.159%;
  • Boswellia BosweIlia sacra Plueck. (syn. (Boswellia carteri Birdw.), rubber resin) fluid extract , titrated 4% in acetyl -11-keto-beta- boswellic acid (AKBA) : 20.923%;
  • Myrrh (Commiphora myrra, Engl., oil -rubber- resin) fluid extract , titrated 4% in furan-dienes : 28.456%;
  • hydroxyl -propyl-methylcellulose capsule ingredient: 12.554%;
  • ethyl cellulose 2.664%
  • medium-chain triglycerides 0.711%
  • titanium dioxide 0.349%
  • oleic acid 0.307%
  • the above described dietary supplement is then used as anti-inflammatory agent.
  • composition of the formulation subjected to experimentations is also included in the Table in Figure 2.
  • THP-1 cells have been kept in a RPMI-1640 ground free from endotoxins and containing: 5,5 mmol/1 glucose, 50 miho ⁇ / ⁇ mercapto-ethanol, 10* bovine fetal serum, 2 mmol/1 glutamine, 1 mmol/1 sodium pyruvate, 10 mmol/1 HEPES.
  • the stimulation in vitro has been performe through the addition of LPS [100 ⁇ g/l] for 4 hours to THP-1 cells seeded in a 12 -well plate ( ⁇ lxl0 6 cells/ml) and incubated at 37°C and 5* C0 2 grown in 75-mm 2 flasks in RPMI-1640 ground enriched with bovine fetal serum and taken to 70* of confluence.
  • the Tumor Necrosis Factor (TNF-a) is an inflammatory cytokine and is a 17-kDa polypeptide mainly produced by activated monocytes and macrophages. This polypeptide mediates some immune and inflammatory responses, including activation and differentiation of monocytes and macrophages, expression of MHC of classes I and II and expression of adhesion molecules on endothelial cells.
  • THP-1 cells (lxlO 6 cells/ml) stimulated with LPS
  • Step 1 the THP-1 cells (lxlO 6 cells/ml) have been pre-treated for 1 hour with two different formulation concentrations:
  • Step 2 The pre-treated TPH-1 cells have been stimulated with LPS [100 pg/l] for 4 hours .
  • the culture ground with the cells has been recovered at the end of the experimental time and the cells have been lysed by using a sonicator .
  • the thereby- obtained supernatant has then been used for the following qualitative and quantitative analyses .
  • Step 3 The supernatant has been used to quantify the TNF-or through ELISA test (Tumor Necrosis
  • Figure 1 shows the results of the stimulation of THP-l cells with LPS, as such and pre-treated with the formulation.
  • THP-l cells The maximum stimulation level of THP-l cells has been obtained by treating them with LPS [100 pg/l] after a 4 -hour incubation.
  • CTR- CTR-
  • columns (B) and (E) show the releases of cytokines from two samples of cells stimulated with LPS, namely the dosage of TNF-a detected on a first and on a second sample of TPH-1 cells, respectively.
  • TNF-a released by the not stimulated cells is greatly different from the concentration of TNF-a released from cells stimulated with LPS .
  • the columns designated as (C) and (F) include the TNF-a released after stimulation with LPS of the THP-1 cells pre-treated with the formulation at the concentration of [0.2 mg/ml] and [67 mg/ml] respectively .
  • D is the percentage variation computed between the sample of TPH-1 cells stimulated with LPS and
  • p is the p value , according to the Student's statistics, computed between sample stimulated with
  • CTR is the control only of the TPH-1 cells not treated with LPS.
  • the in vitro model which has been applied has allowed to test two different concentrations [0.2 mg/ml] and [67 mg/ml] of the formulation according to the invention.
  • TNF-a known mediator of several immune and inflammatory responses, suggesting an anti- inflammatory activity of the tested sample.
  • the Table in Figure 2 shows a composition comprising the above mentioned four active ingredients, plus various ingredients having other functions.
  • the formulation of the invention can be conveniently packaged in capsules, for a practical up-take by a patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A dietary supplement is described, to be used to reduce a release of inflammatory cytokines in patients in whose organism there are leukemic cells of a TPH-1 type, such release being a consequence of a response of the TPH-1 cells to a stimulation with Lipo-polysaccharides (LPS), the dietary supplement comprising the following active ingredients: Buglossoides arvensis seed oil (L.,I.M. Johnst) titrated in essential fatty acids; Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline; Boswellia (Boswellia sacra Flueck. (syn. (Boswellia carteri Birdw.), rubber resin) fluid extract, titrated 4% in acetyl-11-keto-beta-boswellic acid (AKBA); Myrrh (Commiphora myrra, Engl., oil-rubber-resin) fluid extract, titrated 4% in furan-dienes.

Description

DIETARY SUPPLEMENT USED TO REDUCE THE RELEASE OF INFLAM4AT0RY AGENTS AND RELATED USE
The present invention refers to a dietary supplement designed to drastically reduce the inflammatory effects in people affected by leukemia with infections from Gram-negative bacteria.
It is known that monocytes and macrophages synthetize and release in their environment a variety of cytokines and other proteins which perform a central role in the development of acute and chronic inflammations.
THP-1 is a human monocyte leukemic cell line; it is known from scientific literature that these cells are capable of producing pro- inflammatory cytokines (THE- 1 , THE-6 and TNF) and chemokines (THE-8 and MCP-1) in reply to a stimulation by
Lipo-polysaccharides (LPS) .
LPS is a polysaccharide deemed as the main component of the external membrane of Gram-negative bacteria. Recent studies have clarified how LPS is recognized by monocytes and macrophages of the innate immune system; in particular, human monocytes are extremely sensitive to LPS and their response is translated into the expression and the release of many inflammatory cytokines.
From what is stated above, it results that, in a person affected by leukemia, in whose organism there are THP-1 cells, in case of infection by
Gram-negative bacteria, many inflammatory cytokines are released.
EP-A1-3 130 336, US-A1-2008/213357, WO-A1-
2017/029643 and WO-A1-2010/037213 disclose the various components which make the dietary supplement of the present invention; none of them, however, can be used individually to reduce a release of inflammatory cytokines in patients in whose organism there are leukemic cells of a TPH-1 type.
The main object of the present invention is reducing, till almost cancelling, the release of inflammatory cytokines, in patients in whose organism there are leukemic cells of the TPH-1 type, said release being a consequence of the response of said TPH-1 cells to a stimulation with
Lipo-polysaccharides (LPS) .
The above object and the advantages of the invention, as will appear from the following description, are obtained with a dietary supplement as claimed in claim 1, namely comprising the following active ingredients :
Buglossoides arvensis seed oil (L., I.M.
Johnst) titrated in essential fatty acids , preferably Omega 3 and Omega 6;
Ananas (Ananas comosus (L. MERR, stipites) dry extract titrated in bromeline;
Boswellia (Boswellia sacra Flueck . (syn.
Boswellia carteri Birdw . ) , rubber resin) fluid extract , titrated 4% in acetyl - 11-keto-beta- boswellic acid (AKBA) ;
Myrrh (Commiphora myrra, oil-rubber resin) fluid extract , titrated 4% in furan-dienes .
According to a preferred embodiment of the invention, said dietary supplement comprises the above four active ingredients, with the following relative concentrations :
Buglossoides arvensis seed oil (L., I.M.
Johnst ) titrated in essential fatty acids, preferably Omega 3 and Omega 6: 14%;
Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline: 16%;
Boswellia (Boswellia sacra Flueck . (syn. (Boswellia carteri Birdw. ) , rubber resin) fluid extract , titrated 4% in acetyl -11-keto-beta- boswellic acid (AKBA) : 30%;
Myrrh (Commiphora myrra, Engl • 9 oil -rubber- resin) fluid extract , titrated 4% in furan-dienes :
40%.
preferred embodiments and non-trivial variations of the present invention are the subject matter of the dependent claims.
It is intended that all enclosed claims are an integral part of the present description.
It will be immediately obvious that numerous variations and modifications (for example replacements of one or more active ingredients and/or excipients with other of recognized equivalence) can be made to what is described, without departing from the scope off the invention, as appears in the enclosed claims .
The present invention will be better described by some preferred embodiments thereof , provided as a non-limiting example , with reference to the enclosed drawings , in which:
Figure 1 shows the release of inflammatory cytokines TNF-a, due to the stimulation with LPS, of THP-1 cells as such and pre-treated with a formulation according to the invention;
Figure 2 shows a Table with a formulation according to the invention subjected to experimentations ;
Figure 3 shows a Table with the results of experimentations performed on the formulation of
Figure 2.
The dietary supplement of the invention
(formulated below) has been subjected to experimentations to verify its efficacy in inhibiting the release of inflammatory cytokines, simulating in vitro the effect of the cellular membrane of Gram-negative bacteria on THP-1 cells.
The invention therefore deals with a dietary supplement, to be used to reduce the release of inflammatory cytokines in patients in whose organism there are leukemic cells of the TPH-1 type, such release being a consequence of the response of said TPH-1 cells to a stimulation with Lipo-polysaccharides (LPS) ; the dietary supplement of the invention comprises the following active ingredients :
Buglossoides arvensis seed oil (L., I.M.
Johnst ) titrated in essential fatty acids, preferably Omega 3 and Omega 6; Ananas (Ananas comosus (L. MERR, stipites) dry extract titrated in bromeline;
Boswellia (Boswellia sacra Flueck. (syn.
Boswellia carter! Birdw . ) , rubber resin) fluid extract , titrated 4% in acetyl-ll-keto-beta- boswellic acid (AKBA) ;
Myrrh (Commiphora myrra, oil -rubber resin) fluid extract, titrated 4% in furan-dienes.
According to the preferred embodiment , to obtain the best effect, the dietary supplement of the invention comprises the four above active ingredients, with the following relative concentratios :
Buglossoides arvensis seed oil (L. , I.M. Johnst) titrated in essential fatty acids, preferably Omega 3 and Omega 6: 14%;
Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline: 16%;
Boswellia (Boswellia sacra Flueck. (syn. (Boswellia carter! Birdw. ) , rubber resin) fluid extract , titrated 4% in acetyl- 11-keto-beta- boswellic acid (AKBA) : 30%;
Myrrh (Commiphora myrra, Engl., oil-rubber- resin) fluid extract, titrated 4% in furan-dienes : 40%. The above described formulation can be integrated with the addition of:
silicon dioxide ,- hydroxyl-propyl -methylcelluloae ;
DL-or Tocopherol;
ethyl cellulose;
extra-virgin olive oil (Olea europaea L., fructus) ;
glycerol ;
sodium alginate;
medium-chain triglycerides;
rameic chlorophyllin complexes ;
titanium dioxide ,- oleic acid;
stearic acid.
In particular, the above described supplement can be packaged in capsules and have the following global composition:
Buglossoides arvensis seed oil (L., I.M. Johnst) titrated in essential fatty acids, preferably Omega 3 and Omega 6: 9.764%;
Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline: 11.159%;
Boswellia (BosweIlia sacra Plueck. (syn. (Boswellia carteri Birdw.), rubber resin) fluid extract , titrated 4% in acetyl -11-keto-beta- boswellic acid (AKBA) : 20.923%;
Myrrh (Commiphora myrra, Engl., oil -rubber- resin) fluid extract , titrated 4% in furan-dienes : 28.456%;
hydroxyl -propyl-methylcellulose (capsule ingredient) : 12.554%;
silicon dioxide : 0.139%;
DL-a Tocopherol : 1.395%;
ethyl cellulose: 2.664%;
extra-virgin olive oil: 6.138%;
hydroxyl -propyl-methylcellulose : 3.613%;
glycerol: 0.753%;
sodium alginate : 0.621%;
medium-chain triglycerides : 0.711%;
rameic chiorophyl1in complexes : 0.446%;
titanium dioxide: 0.349%;
oleic acid: 0.307%;
stearic acid: 0.006%.
The above described dietary supplement is then used as anti-inflammatory agent.
As such, it is administered in a dosage from
500 mg to 2000 mg.
The composition of the formulation subjected to experimentations is also included in the Table in Figure 2.
THP-1 cells have been kept in a RPMI-1640 ground free from endotoxins and containing: 5,5 mmol/1 glucose, 50 mihoΐ/ΐ mercapto-ethanol, 10* bovine fetal serum, 2 mmol/1 glutamine, 1 mmol/1 sodium pyruvate, 10 mmol/1 HEPES.
Experimentations in vitro have been performed by stimulating the TPH-1 cells with LPS, since it is the major component of the external membrane of Gram-negative bacteria. In this way, it is possible to evaluate the amount of inflammatory cytokines released and, therefore, repeat the experiment by adding the formulation and evaluating the differences in the release of said inflammatory cytokines .
The stimulation in vitro has been performe through the addition of LPS [100 ^g/l] for 4 hours to THP-1 cells seeded in a 12 -well plate (~lxl06 cells/ml) and incubated at 37°C and 5* C02 grown in 75-mm2 flasks in RPMI-1640 ground enriched with bovine fetal serum and taken to 70* of confluence.
The Tumor Necrosis Factor (TNF-a) is an inflammatory cytokine and is a 17-kDa polypeptide mainly produced by activated monocytes and macrophages. This polypeptide mediates some immune and inflammatory responses, including activation and differentiation of monocytes and macrophages, expression of MHC of classes I and II and expression of adhesion molecules on endothelial cells.
The performed experimentation provided for the dosage of TNF-a released following the stimulation of THP-1 cells with LPS. The determination of the concentration of TNF-a in the colture ground has been performed through ELISA (Enzyme-Linked
Immunosorbent Assay) (Cayman Chemical, Michigan
48108 USA) , based on a double-antibody sandwich technique .
The anti-inflammatory effects of the treatment with the formulation has been evaluated by using
THP-1 cells (lxlO6 cells/ml) stimulated with LPS
[100 jzg/l] for 4 hours; afterwards, the concentration of TNF-a possibly present in the cellular culture ground has been detected and quantified.
The experimentations have been performed in three steps :
1 pre-treatment of the TPH-1 cells with the formulation;
2 stimulation with LPS of the cells pre-treated with the formulation;
3 qualitative and quantitative analysis of the experimental results .
Step 1 - the THP-1 cells (lxlO6 cells/ml) have been pre-treated for 1 hour with two different formulation concentrations:
a [0.2 mg/ml] ;
b [67 mg/ml] .
The choice of the concentration [0.2 mg/ml] has been determined by the fact that the daily posology is 2 capsules/day for an adult; every capsule contains 500 mg of active ingredients : therefore, 1 g/day, which in vivo is distributed in about 5 1 of blood . In vitro this corresponds to [0.2 mg/ml] of formulation.
The choice of the concentration [67 mg/ml] has been determined both by the compliance with the accurate experimental conditions of the model in vitro (lxlO6 monocytes/ml of culture ground + LPS
100 pg/l) , and by the consideration that, in vivo, under normal conditions, there are about 10e monocytes per liter of blood; therefore, 0.2 g/1 of formulation potentially have effect on 106 monocytes .
Step 2 - The pre-treated TPH-1 cells have been stimulated with LPS [100 pg/l] for 4 hours . The culture ground with the cells has been recovered at the end of the experimental time and the cells have been lysed by using a sonicator . The thereby- obtained supernatant has then been used for the following qualitative and quantitative analyses .
Step 3 The supernatant has been used to quantify the TNF-or through ELISA test (Tumor Necrosis
Factor-a human EIA Kit, Cayman Chemical, Michigan 48108 USA) . The results for the release of cytokines are included per ml of supernatant .
All experiments have been performed in triplicate . The Student's "T* test for unpaired data has been applied for a comparison between the means, accepting a significance of 5%.
Experimentation results
Figure 1 shows the results of the stimulation of THP-l cells with LPS, as such and pre-treated with the formulation.
The maximum stimulation level of THP-l cells has been obtained by treating them with LPS [100 pg/l] after a 4 -hour incubation.
Columns (A) and (D) show the releases of cytokines from TPH-1 cells not stimulated with LPS
(CTR-) , while columns (B) and (E) show the releases of cytokines from two samples of cells stimulated with LPS, namely the dosage of TNF-a detected on a first and on a second sample of TPH-1 cells, respectively.
It can be noted how the concentration of TNF-a released by the not stimulated cells (CTR-) is greatly different from the concentration of TNF-a released from cells stimulated with LPS .
The columns designated as (C) and (F) include the TNF-a released after stimulation with LPS of the THP-1 cells pre-treated with the formulation at the concentration of [0.2 mg/ml] and [67 mg/ml] respectively .
As can be seen in Figure 1 and in the Table in Figure 3, the formulation at the concentration of
[0.2 mg/ml] has inhibited the release of TNF-a by
6.82%, while at the concentration of [67 mg/ml] has inhibited the release of TNF-a by 99.85%.
The results are included in the Table in Figure 3, as mean ± Standard Deviation (DS) from experiments performed in triplicate.
In the same Table:
D is the percentage variation computed between the sample of TPH-1 cells stimulated with LPS and
25 pre-treated with the formulation vs the sample of TPH-1 cells only stimulated with LPS;
p is the p value , according to the Student's statistics, computed between sample stimulated with
LPS and treated with the formulation with respect to the sample stimulated with LPS;
CTR is the control only of the TPH-1 cells not treated with LPS.
The in vitro model which has been applied has allowed to test two different concentrations [0.2 mg/ml] and [67 mg/ml] of the formulation according to the invention.
Both concentrations has been chosen by taking into account: 1) daily posology; 2) total volume of blood which is present in an adult individual; 3) number of cells (monocytes) present both in vivo in
1 1 of blood, and in vitro in the experimental model followed.
The smaller concentration [0.2 mg/ml] has reduced the measured concentration of TNF-a by 6.82% and the bigger concentration [67 mg/ml] has caused a strong reduction of TNF-a (p=3,4*10"10) (D
= 99.85%) .
In compliance with the test and the experimental conditions used, it can be concluded that the formulation according to the invention, whose composition in included in the Table in
Figure 2, is capable of inhibiting the release of
TNF-a, known mediator of several immune and inflammatory responses, suggesting an anti- inflammatory activity of the tested sample.
The Table in Figure 2 shows a composition comprising the above mentioned four active ingredients, plus various ingredients having other functions.
Other tests performed on similar compositions to the one included in the Table in Figure 2, and comprising one or more of the above active ingredients, have shown a validity in inhibiting the release of TNF-a, even with a lower efficacy than the one shown by the composition included in the Table in Figure 2.
The formulation of the invention can be conveniently packaged in capsules, for a practical up-take by a patient.

Claims

1. Dietary supplement to be used to reduce a release of inflammatory cytokines in patients in whose organism there are leukemic cells of a TPH-1 type, said release being a consequence of a response of said TPH-1 cells to a stimulation with
Lipo-polysaccharides (LPS) , the dietary supplement comprising the following active ingredients:
Buglossoides arvensis seed oil (L., I.M. Johnst) titrated in essential fatty acids;
Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline;
Boswellia (Boswellia sacra Flueck. (syn.
(Boswellia carteri Birdw.), rubber resin) fluid extract, titrated 4% in acetyl-11-keto-beta- boswellic acid (AKBA) ;
Myrrh (Commiphora myrra, Engl., oil-rubber- resin) fluid extract, titrated 4% in furan-dienes .
2. Dietary supplement according to claim 1, characterized in that it comprises said four active ingredients, with the following relative concentrations :
Buglossoides arvensis seed oil (L., I.M.
Johnst) titrated in essential fatty acids: 14%;
Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline: 16%;
Boswellia (Boswellia sacra Flueck. (syn.
(Boswellia carter! Birdw. ) , rubber resin) fluid extract , titrated 4* in acetyl -11 -keto-beta- boswellic acid (AKBΆ) : 30%;
Myrrh (Commiphora myrra, Engl., oil -rubber- resin) fluid extract, titrated 4% in furan-dienes :
40%.
3. Dietary supplement according to claim 2, with an addition of :
silicon dioxide;
hydroxyl -propyl -methylcellulose ;
DL-ot Tocopherol;
ethyl cellulose;
extra-virgin olive oil;
glycerol ;
sodium alginate ;
medium-chain triglycerides ;
rameic chlorophyllin complexes ;
titanium dioxide;
oleic acid;
stearic acid.
4. Dietary supplement according to any one of the previous claims, characterized in that it is packaged in capsules and it has the following global composition:
Buglossoides arvensis seed oil (L. , I.M. Johnst) titrated in essential fatty acids : 9.764%;
Ananas (Ananas comosus, L. MERR, stipites) dry extract titrated in bromeline: 11.159%;
Boswellia (Boswellia sacra Flueck. (syn.
(Boswellia carteri Birdw. ) , rubber resin) fluid extract , titrated 4% in acetyl -11-keto-beta- boswellic acid (AKBA) : 20.923%;
Myrrh (Commiphora myrra, Engl., oil-rubber- resin) fluid extract , titrated 4% in furan-dienes :
28.456%;
hydroxyl -propyl -methylcellulose (capsule ingredient) : 12.554% ;
silicon dioxide : 0.139%
DL-ct Tocopherol: 1.395%
ethyl cellulose : 2.664%
extra-virgin olive oil: 6.138%;
hydroxyl -propyl -methylcellulose : 3.613%;
glycerol: 0.753%;
sodium alginate : 0.621%;
medium-chain triglycerides : 0.711%;
rameic chlorophyl1in complexes : 0.446%;
titanium dioxide: 0.349%;
oleic acid: 0.307%; stearic acid: 0.006%.
5. Use of the dietary supplement according to any one of the previous claims as anti-inflammatory agent .
6. Use according to claim 5, wherein said dietary supplement is administered in a dosage ranging from
500 mg to 2000 mg.
EP19835836.8A 2018-11-19 2019-11-18 Dietary supplement used to reduce the release of inflammatory agents and related use Pending EP3883587A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000010393A IT201800010393A1 (en) 2018-11-19 2018-11-19 Food supplement designed to reduce the release of inflammatory agents and their use
PCT/IT2019/000106 WO2020105070A1 (en) 2018-11-19 2019-11-18 Dietary supplement used to reduce the release of inflammatory agents and related use

Publications (1)

Publication Number Publication Date
EP3883587A1 true EP3883587A1 (en) 2021-09-29

Family

ID=65861505

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19835836.8A Pending EP3883587A1 (en) 2018-11-19 2019-11-18 Dietary supplement used to reduce the release of inflammatory agents and related use

Country Status (3)

Country Link
EP (1) EP3883587A1 (en)
IT (1) IT201800010393A1 (en)
WO (1) WO2020105070A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357810B2 (en) * 2019-10-09 2022-06-14 Brain Health Holding Llc Compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil having synergistic effects for improving memory, focus, and cognitive function, and related methods
IT202000018970A1 (en) 2020-08-03 2022-02-03 Asoltech Srl MYRRH-BASED COMPOSITION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213357A1 (en) * 2007-02-12 2008-09-04 Andrew Bruce Hebard Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications
EP2334312A4 (en) * 2008-10-02 2012-11-28 Nutriquine N V Compositions comprising plant extracts and use thereof for treating inflammation
ITUB20153066A1 (en) * 2015-08-11 2017-02-11 Graal S R L FOOD AND / OR NUTRACEUTICAL COMPOSITION CONTAINING PEA
ITUB20153171A1 (en) * 2015-08-20 2017-02-20 Aboca Spa Societa Agricola COMPOSITION INCLUDING TANNINS

Also Published As

Publication number Publication date
WO2020105070A1 (en) 2020-05-28
IT201800010393A1 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
Camilli et al. β-Glucan–induced reprogramming of human macrophages inhibits NLRP3 inflammasome activation in cryopyrinopathies
Lu et al. Astragalus polysaccharide induces anti-inflammatory effects dependent on AMPK activity in palmitate-treated RAW264. 7 cells
Rink et al. Zinc-altered immune function and cytokine production
Decker et al. Comparative study of cytotoxicity, tumor necrosis factor, and prostaglandin release after stimulation of rat Kupffer cells, murine Kupffer cells, and murine inflammatory liver macrophages
Srikumar et al. Immunomodulatory activity of triphala on neutrophil functions
Mohd Effendy et al. The effects of tualang honey on bone metabolism of postmenopausal women
Witte et al. The Pelargonium sidoides extract EPs 7630 drives the innate immune defense by activating selected MAP kinase pathways in human monocytes
WO2020105070A1 (en) Dietary supplement used to reduce the release of inflammatory agents and related use
Marzulli et al. Immunomodulating and anti-allergic effects of Negroamaro and Koshu Vitis vinifera fermented grape marc (FGM)
Kim et al. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells
Todorova et al. Vitamin B12: Could it be a promising immunotherapy
Lee et al. Anti-inflammatory effects of Allium cepa L. peel extracts via inhibition of JAK-STAT pathway in LPS-stimulated RAW264. 7 cells
Hou et al. Astragalus membranaceus as a Drug Candidate for Inflammatory Bowel Disease: The Preclinical Evidence
Wang et al. Rosmarinic acid protects mice from concanavalin A-induced hepatic injury through AMPK signaling
Rodriguez-López et al. The capacity of differentiation of stromal vascular fraction cells into beige adipocytes is markedly reduced in subjects with overweight/obesity and insulin resistance: effect of genistein
Wang et al. Synergistic anti-inflammatory effects of resveratrol and vitamin E in lipopolysaccharide-induced RAW264. 7 cells
Rühl‐Muth et al. Feeding of a fat‐enriched diet causes the loss of resistance to contact hypersensitivity
Park Anti-allergic and anti-inflammatory activity of Phellinus linteus grown on Panax ginseng
Wang et al. Cichoric acid from extracted Echinacea purpurea induces the proliferation and apoptosis of peripheral blood mononuclear cells from yaks
Farhangi et al. Vitamin A supplementation reduces the Th17-Treg–Related cytokines in obese and non-obese women
Wei et al. The immunosuppressive activity of pseudolaric acid B on T lymphocytes in vitro
Iman et al. In vitro Antiplatelet Activity-Guided Fractionation of Aerial Parts of Melothria maderaspatana.
Cho et al. Dimerized translationally controlled tumor protein-binding peptide 2 attenuates systemic anaphylactic reactions through direct suppression of mast cell degranulation
Goswami et al. Vitamin E reduces hypobaric hypoxia-induced immune responses in male rats
Al-Gareeb et al. Hepatoprotective effects of vitamin c against methotrexate induced acute liver injury: an experimental study

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MAYOLY ITALIA S.P.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240131